NEW YORK (GenomeWeb) — Cellular Research said today that it is collaborating with Seven Bridges Genomics to provide customers with a "complete analysis pipeline" to run RNA sequencing experiments.
Specifically, Seven Bridges will provide an integrated cloud-based informatics platform to manage customers' experiments using Cellular Research's Precise RNA-seq assays.
Cellular Research has launched an early access program for the assays, making the product available to 10 sites. The assays are based on Cellular Research's molecular indexing technology, and are designed to examine large numbers of standard or low-input mRNA samples in high throughput by combining molecular and sample indexing in 96- and 384-sample formats, enabling customers to sequence up to 2,000 samples on one sequencing run without investment in new equipment or extensive training, the company said.
As reported in PCR Insider in February, Palo Alto, Calif.-based Cellular Research commercially launched its first platform, called the Pixel System, for gene expression studies. This product is also based on the molecular barcoding technology, which is similar to DNA barcoding techniques such as amplicon tagging, but instead encodes individual mRNA molecules at the reverse transcription step.
Cellular Research is a three-year-old startup founded by Bay Area molecular biology entrepreneurs including Affymetrix Chairman and Founder Stephen Fodor, Glenn Fu, and Stephen Quake.